CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines
Both will develop cancer vaccine candidates in selected haematological and solid tumour indications
Read More
Tag: CureVac
First patient dosed in pivotal CureVac flu vaccine study
Modified influenza vaccine candidates have been developed in collaboration with GSK
Read More
GSK, CureVac’s COVID-19 vaccine candidate shows promise in preclinical study
Preclinical study shows high protective efficacy in primates for Beta, Delta and Lambda variants
Read More
CureVac’s COVID-19 vaccine misses the mark in late-stage study
Company attributed 47% vaccine efficacy to ‘unprecedented’ amount of circulating variants
Read More
GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data
Vaccine induced strong immune responses in a rat model during preclinical testing
Read More
CureVac’s COVID-19 vaccine begins rolling review with EMA
CureVac’s CVnCoV is currently being investigated in a randomised, placebo-controlled Phase IIb/III clinical trial
Read More
EU signs COVID-19 vaccine deal with CureVac
Initial purchase includes 225 million doses of mRNA-based vaccine
Read More
GSK and CureVac form mRNA tech collaboration
GSK to make equity investment of £130m in CureVac as part of the deal
Read More
Lilly signs up to cancer vaccines with CureVac deal
Eli Lilly has signed up CureVac to develop cancer vaccines based on its mRNA technology, in a deal that could potentially be worth more than $2.6 billion to the German biotech.
Read More
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
